CytomX Therapeutics (CTMX) Tops Q2 EPS by 6c, Misses on Revenue

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of $0.00, $0.06 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.1 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits